Multidrug resistance factor - glycoprotein P in rheumatoid arthritis
https://doi.org/10.14412/1995-4484-2003-1127
Abstract
Objective. To assess expression of P-glycoprotein (Pgp) on peripheral blood (PB) lymphocytes and its changes during therapy in pts with rheumatoid arthritis (RA). Methods. 51 RA pts and 11 healthy donors (control group) were examined. 35 pts were followed up. 20 of them were treated with methotrexate (MT) and 15 with glucocorticosteroid (GCS) pulse therapy (PT). Pgp expression was examined with flow cytofluorometry with monoclonal antibodies (UIC2 PE, Immunotech). Results. Pgp expression on PB lymphocytes in RA was significantly more prominent (29,3 29,9 %) than in control group (2,5 2,0 %), P<0,01. Pgp expression did not depend on pts age and sex, duration and stage of the disease, presence or absence history of disease modifying drugs therapy. PT with GCS but not MT significantly decreased Pgp expression (from 57,2±27,0 % to 28,8135,2 %, r<0,05). Conclusion. RA patients have increased Pgp expression, which is probably biologically sensible but clinically unfavourable response of immunocompetent cells to durable application of such foreign substances as medications. PT with GCS decrease Pgp expression on lymphocytes while treatment with MT does not change it.
References
1. <div><p>Барышников А.Ю., Степанова Е.В. Проблемы лекарственной резистентности. Материалы III ежегодной Российской онкологической конференции 29 ноября - I декабря 1999 г., С.-Петербург.</p><p>Насонова В.А., Бунчук Н.В. Ревматические болезни, 1997, 257-261.</p><p>Насонов Е.Л. 50 лет применения метотрексата в ревматологии. Русс. мед. журнал, 2000, 8-9, 372-376.</p><p>Насонов Е.Л., Соловьев С.К., Лашина НЛО. Лечение ревматоидного артрита: роль глкжокортикоидов. Клин, медицина, 1999, 4, 4-8.</p><p>Сигндин ЯА, Лукина Г.В. Новые подходы к анализу патогенеза и патогенетической терапии ревматоидного артрита. Научно-практич. ревматол., 2001, 5, 4-11.</p><p>Ставровская А.А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток. Биохимия, 2000, 65, 1, 112-126.</p><p>Bologna С., Viu P., Picot М., et а1. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective observational study. Br. J. Rheumatol., 1997, 36, 5, 535-540.</p><p>Cutolo М., Sulli A., Pizzomi C., et al. Anti-inflammatory mehanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 2001, 60, 729-735.</p><p>Hendrich C., Kuipers J., Kolanus W., et al. Activation of CD16+ effector cells by rheumatoid factor complex. Role of natural killer cells in rheumatoid arthritis. Arthritis Rheum., 1991,34, 4,423-31.</p><p>Inazuka М., Tahira Т., Horiuchi Т., et al. Analysis of p53 tumor supressor gene on somatic mutation in rheumatoid arthritis sinovium. Rheumatol., 2000, 39, 3, 262-266.</p><p>Isomaki P., Soderstrom K.-O., Punnonen J. et al. Expression of Bcl-2 in rheumatoid arthritis. Br. J. Rheumatol., 1996, 35, 611-619.</p><p>Jorgensen C., Sun. R., Rossi J. et al. Expression of multidrug resistance gene in human rheumatoid synovium. Rheumatol. Int., 1995, 15, 2, 83-6.</p><p>Kirsch A.H., Mahmood A.A., Endres J., et al. Apoptosis of human T-ceIIs: induction by glucocorticoids or surface receptor ligation in vitro and in vivo. J.Biol. Regul. Homeost. Agents., 1999,13, 2, 80-9.</p><p>Kusaba М., Honda J., Fukuda Т., et al. Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J. Rheumatol., 1998, 25,8,1466-71.</p><p>Llorente L., Richaud-Patin Y., Diaz-Borjon A., et al. Increased P-glycoprotein activity in lymphocytes from rheumatoid artlmtis patients might influence disease outcome. Joint Bone Spine, 2000, 67,1, 30-9.</p><p>Maillefert J., Duchamp O., Solary E., et al. Effect of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. Ann. Rheum. Dis, 2000,59,146-148.</p><p>Maillefert J., Maynadie М., Tebib J. et al. Expression of multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br. J. Rheumatol. 1996, 35,430-435.</p><p>Rahman P., Hefferton D., Khraishi М., et al. Over expression of P-glycoprotein transporter activity accounts for a subset of methotrexate resistance in RA. Arthr. Rheum., 2000,43,9, 158.</p><p>Rahman P., Hefferton D., Robb D. Increased MDR1 P- glycoprotein expression in methotraxate resistance: comment on the article by Yudoh et al. Arthr. Rheum., 2000,43,7,1661-2.</p><p>Salmon S., Dalton W. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypotesis. J.Rheumatol., 1996, 44, 97-101.</p><p>Schirmer М., Vallejo A., Weyand C., et al. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. J.Immunol., 1998, 15,161,2,1018-25.</p><p>Yudoh K., Matsuno H., Nakazawa F. et al. Increased expression of multidrug resistance of P-glycoprotein on Thl cells correlates with drug resistance in rheumatoid arthritis. Arthr. Rheum., 1999, 42,9, 2014-18.</p></div><br />
Review
For citations:
Kolosova I.P. Multidrug resistance factor - glycoprotein P in rheumatoid arthritis. Rheumatology Science and Practice. 2003;41(1):19-23. (In Russ.) https://doi.org/10.14412/1995-4484-2003-1127
Views:
830
Email this article 